5 rezultatima
BACKGROUND
Thapsigargin (TG) is a naturally-occurring compound that is highly specific for inhibiting the sarco/endoplasmic reticulum and endoplasmic reticulum Ca.sup.2+-ATPase pump (SERCA). The inventors recently identified TG as a modulator of Notch (Roti G., et al., "Complementary genomic screens
FIELD OF THE INVENTION
The present invention relates to a method of treating a solid tumor, and in particular, to a method involving hypoxic stress as one component and protein kinase C activation as another component.
REFERENCES
Cook, P. F., et al., Biochem. 21: 5794-5799 (1982).
Culver, K., et
FIELD OF THE INVENTION
The invention generally relates to the treatment of cancer, and, more specifically, to the treatment of tumors, including solid tumors and their metastases, without radiation or standard chemotherapeutic agents. In a preferred embodiment, the invention relates to the
FIELD OF THE INVENTION
The invention generally relates to the treatment of cancer, and, more specifically, to the treatment of tumors, including solid tumors and their metastases, without radiation or standard chemotherapeutic agents. In a preferred embodiment, the invention relates to the
FIELD OF THE INVENTION
The invention generally relates to the treatment of cancer, and, more specifically, to the treatment of tumors, including solid tumors and their metastases, without radiation or standard chemotherapeutic agents. In a preferred embodiment, the invention relates to the